This finding, was confirmed by in vivo experiments, validated by the sequential use of LSD1 inhibitors and anti-PD-1 inhibitors as a potential strategy for effective and more durable responses to anti-PD-1 inhibitors in melanoma [66,90]. The gene discussed is PDCD1; the disease is melanoma.